LXEO Stock Overview
Operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Lexeo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.12 |
| 52 Week High | US$22.33 |
| 52 Week Low | US$7.86 |
| Beta | 0 |
| 11 Month Change | 3.15% |
| 3 Month Change | -3.64% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 10.65% |
Recent News & Updates
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Recent updates
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's
Jan 29Shareholder Returns
| LXEO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 35.8% | 0.6% | 0.3% |
| 1Y | n/a | 27.8% | 38.3% |
Return vs Industry: Insufficient data to determine how LXEO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how LXEO performed against the US Market.
Price Volatility
| LXEO volatility | |
|---|---|
| LXEO Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LXEO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LXEO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 69 | R. Townsend | www.lexeotx.com |
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease.
Lexeo Therapeutics, Inc. Fundamentals Summary
| LXEO fundamental statistics | |
|---|---|
| Market cap | US$367.64m |
| Earnings (TTM) | -US$77.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs LXEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXEO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$57.76m |
| Gross Profit | -US$57.76m |
| Other Expenses | US$19.46m |
| Earnings | -US$77.21m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LXEO perform over the long term?
See historical performance and comparison